Rostaporfin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Rostaporfin
Accession Number
DB06659
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Rostaporfin
  • SnET2
  • Tin ethyl etiopurpurin
International/Other Brands
Photrex
Categories
UNII
466G63QE7G
CAS number
284041-10-7
Weight
Average: 728.93
Monoisotopic: 729.201283
Chemical Formula
C37H42ClN4O2Sn
InChI Key
DMAHZCZCPVOYGS-ZLSDMPCXSA-L
InChI
InChI=1S/C37H43N4O2.ClH.Sn/c1-10-23-19(6)29-17-33-25(12-3)21(8)34(40-33)26-15-27(36(42)43-14-5)37(13-4)22(9)30(41-35(26)37)18-32-24(11-2)20(7)28(39-32)16-31(23)38-29;;/h15-18,22H,10-14H2,1-9H3,(H-,38,39,40,41,42);1H;/q-1;;+4/p-2/t22-,37-;;/m1../s1
IUPAC Name
tin(4+) (5R,26S)-4-(ethoxycarbonyl)-5,11,16,21-tetraethyl-12,17,22,26-tetramethyl-7,23,24,25-tetraazahexacyclo[18.2.1.1^{5,8}.1^{10,13}.1^{15,18}.0^{2,6}]hexacosa-1(23),2(6),3,8,10(25),11,13,15,17,19,21-undecaene-7,24-diide chloride
SMILES
[Cl-].[Sn+4].CCOC(=O)C1=CC2=C3[N-]\C(=C/C4=N/C(=C\C5=C(CC)C(C)=C([N-]5)\C=C5/N=C2C(C)=C5CC)/C(C)=C4CC)[C@@H](C)[C@]13CC

Pharmacology

Indication

Investigated for use/treatment in macular degeneration.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Porfimer sodiumRostaporfin may increase the photosensitizing activities of Porfimer sodium.
VerteporfinRostaporfin may increase the photosensitizing activities of Verteporfin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
32702297

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
3Unknown StatusTreatmentMacular Degeneration1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP7.67ALOGPS
logP10.24ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)12.37ChemAxon
pKa (Strongest Basic)5.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area77.86 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity176.37 m3·mol-1ChemAxon
Polarizability70.92 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:46 / Updated on June 04, 2019 06:27